Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)
PURPOSE - - In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related mortality (TRM) limits its broader use in elderly patients with MDS. The present prospective...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 20, 2021
|
| In: |
Journal of clinical oncology
Year: 2021, Jahrgang: 39, Heft: 30, Pages: 3318-3327 |
| ISSN: | 1527-7755 |
| DOI: | 10.1200/JCO.20.02724 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1200/JCO.20.02724 Verlag, lizenzpflichtig, Volltext: https://ascopubs.org/doi/10.1200/JCO.20.02724 
|
| Verfasserangaben: | Nicolaus Kröger, MD; Katja Sockel, MD; Christine Wolschke, MD; Wolfgang Bethge, MD; Richard F. Schlenk, MD, Dominik Wolf, MD; Michael Stadler, MD; Guido Kobbe, MD; Gerald Wulf, MD; Gesine Bug, MD; Kerstin Schäfer-Eckart, MD; Christof Scheid, MD; Florian Nolte, MD; Jan Krönke, MD; Matthias Stelljes, MD; Dietrich Beelen, MD; Marion Heinzelmann; Detlef Haase, MD; Hannes Buchner, PhD; Gabriele Bleckert, PhD; Aristoteles Giagounidis, MD; Uwe Platzbecker, MD; on behalf of the German MDS Study Group and the German Cooperative Transplant Study Group |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1796681423 | ||
| 003 | DE-627 | ||
| 005 | 20230428010635.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220325s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.20.02724 |2 doi | |
| 035 | |a (DE-627)1796681423 | ||
| 035 | |a (DE-599)KXP1796681423 | ||
| 035 | |a (OCoLC)1341458093 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kröger, Nicolaus |d 1959- |e VerfasserIn |0 (DE-588)112156533 |0 (DE-627)477107354 |0 (DE-576)167115103 |4 aut | |
| 245 | 1 | 0 | |a Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study) |c Nicolaus Kröger, MD; Katja Sockel, MD; Christine Wolschke, MD; Wolfgang Bethge, MD; Richard F. Schlenk, MD, Dominik Wolf, MD; Michael Stadler, MD; Guido Kobbe, MD; Gerald Wulf, MD; Gesine Bug, MD; Kerstin Schäfer-Eckart, MD; Christof Scheid, MD; Florian Nolte, MD; Jan Krönke, MD; Matthias Stelljes, MD; Dietrich Beelen, MD; Marion Heinzelmann; Detlef Haase, MD; Hannes Buchner, PhD; Gabriele Bleckert, PhD; Aristoteles Giagounidis, MD; Uwe Platzbecker, MD; on behalf of the German MDS Study Group and the German Cooperative Transplant Study Group |
| 246 | 3 | 0 | |a five |
| 264 | 1 | |c July 20, 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 25.03.2022 | ||
| 520 | |a PURPOSE - - In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related mortality (TRM) limits its broader use in elderly patients with MDS. The present prospective multicenter study compared HSCT following 5-aza pretreatment with continuous 5-aza treatment in patients with higher-risk MDS age 55-70 years. - - METHODS - - One hundred ninety patients with a median age of 63 years were enrolled. Patients received 4-6 cycles of 5-aza followed by HLA-compatible HSCT after reduced-intensity conditioning or by continuous 5-aza if no donor was identified. - - RESULTS - - Twenty-eight patients did not fulfill inclusion criteria (n = 20), died (n = 2) withdrew informed consent (n = 5), or were excluded for an unknown reason (n = 1). 5-aza induction started in 162 patients, but only 108 (67%) were eligible for subsequent allocation to HSCT (n = 81) or continuation of 5-aza (n = 27) because of disease progression (n = 26), death (n = 12), or other reasons (n = 16). Seven percent died during 5-aza before treatment allocation. The cumulative incidence of TRM after HSCT at 1 year was 19%. The event-free survival and overall survival after 5-aza pretreatment and treatment allocation at 3 years were 34% (95% CI, 22 to 47) and 50% (95% CI, 39 to 61) after allograft and 0% and 32% (95% CI, 14 to 52) after continuous 5-aza treatment (P < .0001 and P = .12), respectively. Fourteen patients progressing after continuous 5-aza received a salvage allograft from an alternative donor, and 43% were alive at last follow-up. - - CONCLUSION - - In older patients with MDS, reduced-intensity conditioning HSCT resulted in a significantly improved event-free survival in comparison with continuous 5-aza therapy. Bridging with 5-aza to HSCT before is associated with a considerable rate of dropouts because of progression, mortality, and adverse events. | ||
| 700 | 1 | |a Sockel, Katja |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wolschke, Christine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bethge, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Wolf, Dominik |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stadler, Michael |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kobbe, Guido |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wulf, Gerald |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bug, Gesine |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schäfer-Eckart, Kerstin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Scheid, Christof |e VerfasserIn |4 aut | |
| 700 | 1 | |a Nolte, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Krönke, Jan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Stelljes, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Beelen, Dietrich |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinzelmann, Marion |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haase, Detlef |e VerfasserIn |4 aut | |
| 700 | 1 | |a Buchner, Hannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bleckert, Gabriele |e VerfasserIn |4 aut | |
| 700 | 1 | |a Giagounidis, Aristoteles |e VerfasserIn |4 aut | |
| 700 | 1 | |a Platzbecker, Uwe |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology |d Alexandria, Va. : American Society of Clinical Oncology, 1983 |g 39(2021), 30, Seite 3318-3327 |h Online-Ressource |w (DE-627)313116962 |w (DE-600)2005181-5 |w (DE-576)090887018 |x 1527-7755 |7 nnas |a Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study) |
| 773 | 1 | 8 | |g volume:39 |g year:2021 |g number:30 |g pages:3318-3327 |g extent:11 |a Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study) |
| 856 | 4 | 0 | |u https://doi.org/10.1200/JCO.20.02724 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://ascopubs.org/doi/10.1200/JCO.20.02724 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20220325 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 999 | |a KXP-PPN1796681423 |e 4100442580 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 25.03.2022"],"person":[{"display":"Kröger, Nicolaus","given":"Nicolaus","family":"Kröger","role":"aut"},{"given":"Katja","display":"Sockel, Katja","role":"aut","family":"Sockel"},{"display":"Wolschke, Christine","given":"Christine","role":"aut","family":"Wolschke"},{"role":"aut","family":"Bethge","given":"Wolfgang","display":"Bethge, Wolfgang"},{"role":"aut","family":"Schlenk","display":"Schlenk, Richard Friedrich","given":"Richard Friedrich"},{"role":"aut","family":"Wolf","display":"Wolf, Dominik","given":"Dominik"},{"family":"Stadler","role":"aut","display":"Stadler, Michael","given":"Michael"},{"role":"aut","family":"Kobbe","display":"Kobbe, Guido","given":"Guido"},{"role":"aut","family":"Wulf","display":"Wulf, Gerald","given":"Gerald"},{"family":"Bug","role":"aut","given":"Gesine","display":"Bug, Gesine"},{"display":"Schäfer-Eckart, Kerstin","given":"Kerstin","family":"Schäfer-Eckart","role":"aut"},{"given":"Christof","display":"Scheid, Christof","role":"aut","family":"Scheid"},{"family":"Nolte","role":"aut","display":"Nolte, Florian","given":"Florian"},{"display":"Krönke, Jan","given":"Jan","family":"Krönke","role":"aut"},{"family":"Stelljes","role":"aut","given":"Matthias","display":"Stelljes, Matthias"},{"family":"Beelen","role":"aut","display":"Beelen, Dietrich","given":"Dietrich"},{"role":"aut","family":"Heinzelmann","given":"Marion","display":"Heinzelmann, Marion"},{"display":"Haase, Detlef","given":"Detlef","family":"Haase","role":"aut"},{"display":"Buchner, Hannes","given":"Hannes","role":"aut","family":"Buchner"},{"given":"Gabriele","display":"Bleckert, Gabriele","family":"Bleckert","role":"aut"},{"display":"Giagounidis, Aristoteles","given":"Aristoteles","family":"Giagounidis","role":"aut"},{"role":"aut","family":"Platzbecker","display":"Platzbecker, Uwe","given":"Uwe"}],"recId":"1796681423","language":["eng"],"name":{"displayForm":["Nicolaus Kröger, MD; Katja Sockel, MD; Christine Wolschke, MD; Wolfgang Bethge, MD; Richard F. Schlenk, MD, Dominik Wolf, MD; Michael Stadler, MD; Guido Kobbe, MD; Gerald Wulf, MD; Gesine Bug, MD; Kerstin Schäfer-Eckart, MD; Christof Scheid, MD; Florian Nolte, MD; Jan Krönke, MD; Matthias Stelljes, MD; Dietrich Beelen, MD; Marion Heinzelmann; Detlef Haase, MD; Hannes Buchner, PhD; Gabriele Bleckert, PhD; Aristoteles Giagounidis, MD; Uwe Platzbecker, MD; on behalf of the German MDS Study Group and the German Cooperative Transplant Study Group"]},"origin":[{"dateIssuedDisp":"July 20, 2021","dateIssuedKey":"2021"}],"relHost":[{"corporate":[{"role":"isb","display":"American Society of Clinical Oncology"}],"disp":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)Journal of clinical oncology","type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"official journal of the American Society of Clinical Oncology"},{"title":"JCO"},{"title":"Journal of clinical oncology legacy archive (ASCO)"}],"language":["eng"],"part":{"pages":"3318-3327","extent":"11","issue":"30","text":"39(2021), 30, Seite 3318-3327","year":"2021","volume":"39"},"pubHistory":["1.1983 -"],"note":["Fortsetzung der Druck-Ausgabe","Gesehen am 22.05.23"],"title":[{"title":"Journal of clinical oncology","subtitle":"JCO : an American Society of Clinical Oncology journal","title_sort":"Journal of clinical oncology"}],"id":{"zdb":["2005181-5"],"eki":["313116962"],"issn":["1527-7755"]},"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisherPlace":"Alexandria, Va. ; Baltimore, Md. [u.a.]","dateIssuedKey":"1983","dateIssuedDisp":"1983-","publisher":"American Society of Clinical Oncology ; Lippincott Williams & Wilkins"}],"recId":"313116962"}],"id":{"doi":["10.1200/JCO.20.02724"],"eki":["1796681423"]},"physDesc":[{"extent":"11 S."}],"title":[{"title":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)","title_sort":"Comparison between 5-azacytidine treatment and allogeneic stem-cell transplantation in elderly patients with advanced MDS according to donor availability (VidazaAllo Study)"}],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a KROEGERNICCOMPARISON2020 | ||